Varian Medical Systems Inc. (VAR)

131.59
0.71 0.54
NYSE : Health Technology
Prev Close 130.88
Open 130.93
Day Low/High 130.92 / 131.94
52 Wk Low/High 101.42 / 142.50
Volume 141.41K
Avg Volume 563.90K
Exchange NYSE
Shares Outstanding 90.95M
Market Cap 12.01B
EPS 1.60
P/E Ratio 31.90
Div & Yield N.A. (N.A)

Rally Potential Remains

Despite a try at a bottom, the market is still oversold, but oil's crushing move to the downside was the real news.

Wednesday's Healthcare Winners & Losers

FDA approvals can't seem to stimulate the sector.

Ride Ahead May Be Bumpy

Few barriers seem to exist between the current levels and the November lows.

Dykstra: Varian's Steady Performance

The calls here should once again reward investors. Plus, another look at the Stat Book.

Cramer's 'Mad Money Lightning Round': Bank of America the Beautiful

Cramer said that the stock's risk/reward is 'a thing of beauty.'

Dykstra: Bullish on Varian Medical Options

Its reaction to recent troubles bodes well for the options.

Thursday's Analysts' Upgrades and Downgrades

Who made what calls.

Real Story: Clearing the Bar

Expectations are low, helping the market rise above them. But NYSE floor trader Peter Costa says enthusiasm is missing.

Friday's Winners & Losers: Lubrizol

Shares are greased up after the company puts first-quarter earnings well ahead of views.

Varian Slips on Outlook

Shares decline.

Varian OKs Share Buyback

It plans the repurchase of 4.5 million shares.

Varian Medical's Profit Climbs

Varian Medical's Profit Climbs

Robust demand boosts revenue and the bottom line.

Cramer's 'Mad Money Lightning Round': Hey St. Jude

Cramer's 'Mad Money Lightning Round': Hey St. Jude

Boston Sci's expected stent-sales shortfall should make St. Jude a cheaper play.

Cramer's 'Mad Money' Recap: Get In the GameStop

Cramer's 'Mad Money' Recap: Get In the GameStop

Even though EA has the wildly popular Madden NFL game, GameStop is better positioned, says Cramer.

Cramer's 'Mad Money Lightning Round': Barr None

Cramer's 'Mad Money Lightning Round': Barr None

Cramer says Merck, Pfizer and Schering-Plough are all better than Barr Pharma.

Varian Medical Taps Vice President

Varian Medical Taps Vice President

Tai-Yun Chen was controller.

RealMoney's Best Blogs

The week's highlights from the site's five bloggers: Jim Cramer, Rev Shark, Cody Willard, Steve Smith and Tony Crescenzi.

Cramer's 'Mad Money' Recap: Tricking Terror

Cramer goes against the herd when it comes to playing the market after a terrorist threat.

RealMoney Radio: Market Muscle

Cramer says stocks are resilient to the news of a foiled terrorist plot.

RealMoney Radio Recap: Cyclical Fear

RealMoney Radio Recap: Cyclical Fear

Cramer says you still need to stay away from stocks that have exposure to the economy.

RealMoney Radio: All's Wellness at Philips

RealMoney Radio: All's Wellness at Philips

Cramer sees a merger with Varian, an oncology radiation company.

Cramer's 'Mad Money' Recap: A Muzzle for Talking Heads

Cramer's 'Mad Money' Recap: A Muzzle for Talking Heads

Cramer offers a lesson on diagnostics to help investors pick stocks like the pros.

Cramer's 'Mad Money Lightning Round': A Good Prognosis for Varian Medical

Cramer's 'Mad Money Lightning Round': A Good Prognosis for Varian Medical

Cramer didn't mince words when it came to this stock.

Varian Medical Gets U.K. Contract

A cancer-care upgrade results in a machine order.

Today's Health Winners and Losers

Pharmacopeia gets a big lift after announcing a drug discovery pact with Cephalon.

Varian Medical Earnings Rise

Shares fall 2%.

Markets Finally Decide to Follow Pattern

The cycle we've seen since late November implies we'll see a pullback of two to three weeks.

Market May Have Squandered a Chance

Instead of vaulting old highs on good Arms Index numbers, indices have been reluctant to get going.

Varian Medical Gets Bangladesh Pact

Varian Medical Gets Bangladesh Pact

Public hospitals will get four linear accelerators.

Today's Health Winners and Losers

Alexion jumps on positive trial results, while CNS falls after a weak profit report.

TheStreet Quant Rating: B (Buy)